UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

## NOTICE OF ALLOWANCE AND FEE(S) DUE

31496

7500

01/20/2011

SMITH PATENT CONSULTING, LLC 515 East Braddock Road Suite B ALEXANDRIA, VA 22314

EXAMINER				
KIM, ALEXANDER D				
ART UNIT	PAPER NUMBER			
1656				

DATE MAILED: 01/20/2011

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/594,455	06/22/2007	Michael Kretschmar	LNK-020	9277

TITLE OF INVENTION: PRODUCTION OF A VON WILLEBRAND FACTOR PREPARATION USING HYDROXYLAPATITE

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1510	\$300	\$0	\$1810	04/20/2011

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

#### HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

#### PART B - FEE(S) TRANSMITTAL

### Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE

Commissioner for Patents P.O. Box 1450

Alexandria, Virginia 22313-1450 (571)-273-2885 or <u>Fax</u>

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for

maintenance fee notifications. Note: A certificate of mailing can only be used for domestic mailings of the CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address) Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. 31496 7590 01/20/2011 Certificate of Mailing or Transmission SMITH PATENT CONSULTING, LLC I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below. 515 East Braddock Road Suite B ALEXANDRIA, VA 22314 (Depositor's name (Signature (Date APPLICATION NO. FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. FILING DATE 10/594.455 06/22/2007 LNK-020 9277 Michael Kretschmar TITLE OF INVENTION: PRODUCTION OF A VON WILLEBRAND FACTOR PREPARATION USING HYDROXYLAPATITE APPLN. TYPE SMALL ENTITY ISSUE FEE DUE PUBLICATION FEE DUE PREV. PAID ISSUE FEE TOTAL FEE(S) DUE DATE DUE nonprovisional NO \$1510 \$300 \$0 \$1810 04/20/2011 **EXAMINER** ART UNIT CLASS-SUBCLASS KIM, ALEXANDER D 1656 530-413000 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). 2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. or agents OR, alternatively, (2) the name of a single firm (having as a member a ☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) 4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above) 4a. The following fee(s) are submitted: lssue Fee A check is enclosed. Publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached. The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number \_\_\_\_\_\_ (enclose an extra copy of this fo Advance Order - # of Copies \_ (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. ■ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office. Authorized Signature Date Typed or printed name Registration No. This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/594,455	06/22/2007	Michael Kretschmar	LNK-020	9277
31496 7:	590 01/20/2011		EXAM	INER
SMITH PATENT CONSULTING, LLC		KIM, ALEXANDER D		
515 East Braddock	Road		ART UNIT	PAPER NUMBER
Suite B ALEXANDRIA, V	/A 22314		1656 DATE MAILED: 01/20/201	1

# **Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)**

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 420 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 420 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 (571)-272-4200.

	Application No.	Applicant(s)				
	10/594,455	KRETSCHMAR ET	ΓΔΙ			
Notice of Allowability	Examiner	Art Unit	712.			
	ALEXANDER D. KIM	l 1656				
	ALLXANDER D. KIIV	1 1000				
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOS or other appropriate co GHTS. This application	SED in this application. If not include the mailed in due to mailed in due to the mailed in the mail	ded e course. <b>THIS</b>			
1. This communication is responsive to <u>11/09/2010</u> .						
2. X The allowed claim(s) is/are 2.7-11.14-18 and 20.						
<ul> <li>3.  Acknowledgment is made of a claim for foreign priority ur</li> <li>a)  All b)  Some* c)  None of the:</li> <li>1.  Certified copies of the priority documents have</li> </ul>	•	a)-(d) or (f).				
2. ☐ Certified copies of the priority documents have		lication No				
Copies of the certified copies of the priority does not be certified.	• •		ation from the			
International Bureau (PCT Rule 17.2(a)).	sumonito navo boom ro	oon ou in the national stage applie				
* Certified copies not received:						
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.			equirements			
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give			NOTICE OF			
5. CORRECTED DRAWINGS ( as "replacement sheets") mus	t be submitted.					
(a) I including changes required by the Notice of Draftspers	on's Patent Drawing R	Review ( PTO-948) attached				
1)  hereto or 2) to Paper No./Mail Date						
<ul><li>(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date</li></ul>	(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date					
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).						
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.						
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. ☐ Notice	of Informal Patent Application				
2.  Notice of Draftperson's Patent Drawing Review (PTO-948)		ew Summary (PTO-413),				
3. Information Disclosure Statements (PTO/SB/08),	Pape 7. ⊠ Exami	r No./Mail Date iner's Amendment/Comment				
Paper No./Mail Date 4.  Examiner's Comment Regarding Requirement for Deposit		iner's Statement of Reasons for Al	lowance			
of Biological Material	9. ☐ Other					
/Alexander D Kim/		<del></del>				
Examiner, Art Unit 1656						

### **DETAILED ACTION**

# Application Status

1. In response to the previous Office action, a Final rejection (mailed on 09/13/2010), Applicants filed a response and amendment received on 11/09/2010, which were not entered in view of Advisory Action mailed out on 11/26/2010.

Thus, according to claims filed on 07/15/2010, claims 2, 4-18, 20 and 24 are pending.

However, in view of Examiner's amendment set forth below, claims 2, 7-11, 14-18 and 20 are allowed.

## Terminal disclaimers

2. The terminal disclaimers filed on 11/19/2010 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of US Pat. 7,863,420 which is issued from US patent application number 10/594,453 has been reviewed and is accepted. The terminal disclaimers have been recorded.

#### Examiner's amendment to the Claims

3. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Art Unit: 1656

Authorization for this examiner's amendment shown below was given by Chalin Smith on Jan. 7, 2011.

Replace any previous claim set with the following claims.

1. Canceled.

2. A process for purifying wild-type von Willebrand factor (VWF) from a plasma fraction

comprising steps of:

(i) providing a sample of plasma fraction containing wild-type VWF and one or more

contaminating proteins comprising fibronectin and/or fibrinogen;

(ii) preparing the sample of plasma fraction in a first running buffer at pH of 7.0-7.5 that

consists essentially of 10-50 mM sodium and/or potassium phosphate,

(iii) performing flow chromatography by loading the sample of plasma fraction to a

hydroxylapatite matrix under conditions that 90% or more of fibronectin and/or fibrinogen bind

to the hydroxylapatite matrix, while at the same time, less than 10% of the wild-type VWF bind

to the hydroxylapatite matrix thereby providing a flow through fraction(s) containing purified

wild-type VWF, wherein the flow chromatography is performed with the first running buffer;

and

(iv) purifying wild-type VWF by collecting unbound wild-type VWF from the flow

through fraction(s).

3-6. Cancelled.

Art Unit: 1656

7. The process according to claim 2, further comprising step of:

(v) performing binding chromatography by loading the purified wild-type VWF to

hydroxylapatite matrix under a condition such that the wild-type VWF is bound to a

hydroxylapatite matrix and then subsequently eluted, wherein the flow chromatography is

performed with a second running buffer at pH 5.5-6.8.

8. The process according to claim 7, wherein the step (v) comprises: (a) binding the wild-type

VWF to the hydroxylapatite matrix, (b) washing out impurities, and (c) eluting the wild-type

VWF thereby further purifying the wild-type VWF.

9. The process according to claim 8, wherein the step (a) is performed by the second running

buffer with 1 to 200 mM sodium and/or potassium phosphate.

10. The process according to claim 8, wherein the step (b) is performed by the second running

buffer with 100 to 300 mM sodium and/or potassium phosphate.

11. The process according to claim 8, wherein the step (c) is performed with the second running

buffer with 200 to 500 mM sodium and/or potassium phosphate.

12-13. Cancelled.

Art Unit: 1656

14. The process according to claim 2, wherein the sample of plasma fraction in step (i) has been

previously purified.

15. The process according to claim 2, wherein the sample of plasma fraction in step (i) comprises

a separately purified cryoprecipitate solution.

16. The process according to claim 2, wherein the sample of plasma fraction in step (i) comprises

a cryoprecipitate solution precipitated with aluminum hydroxide.

17. The process according to claim 2, wherein the sample plasma fraction in step (i) comprises a

chromatographically pre-purified cryoprecipitate solution precipitated with aluminum hydroxide.

18. The process according to claim 2, further comprising the step of performing a pH

precipitation prior to step of carrying out flow chromatography with hydroxylapatite matrix to

separate fibronectin.

19. Canceled.

20. The process according to claim 2, wherein the hydroxylapatite is fluoroapatite.

21-24. Canceled.

Art Unit: 1656

### Statement of Reasons for Allowance

4. Claims 2, 7-11, 14-18 and 20 are allowed. The following is an examiner's statement of reasons for allowance:

The instant invention is drawn to a process for purifying wild-type von Willebrand factor from a plasma as shown in claim 2 above. Although, a protein purification method using hydroxylapatite is well known in the art, removing of fibronectin (and/or fibrinogen) from VWF containing plasma sample under a condition which results in 90% or more of fibronectin and/or fibrinogen binds to the hydroxylapatite matrix while majority of VWF protein (i.e., more than 90%, for example) does not bind to the hydroxylapatite (thereby collection of flow through fractions provides purification of VWR), wherein the conditions are created by preparing said plasma sample under the running buffer noted in step (ii) of claim 2, is novel and unobvious over hydroxylapatite chromatography purification process in the art.

In view of the examiner's amendment and approval of terminal disclaimers, all outstanding objection and rejections are withdrawn.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance.

Art Unit: 1656

### Conclusion

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALEXANDER D. KIM whose telephone number is (571)272-5266. The examiner can normally be reached on 9AM-5:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath Rao can be reached on (571) 272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Alexander D Kim/ Examiner, Art Unit 1656